175589-02-3

Basic information

• Product Name: 5-BROMO-2-(AMINOMETHYL)-1,3-DIFLUOROBENZENE
• Synonyms: 5-BROMO-2-(AMINOMETHYL)-1,3-DIFLUOROBENZENE;4-BROMO-2,6-DIFLUORO-BENZYLCHLORIDE;5-BROMO-2-(CHLOROMETHYL)-1,3-DIFLUOROBENZENE;5-Bromo-2-(chloromethyl)-1,3-difluorobenzene, 4-Bromo-alpha-chloro-2,6-difluorotoluene
• CAS NO: 175589-02-3
• Molecular Formula: C7H6BrF2N
• Molecular Weight: 222.03
• Mol File: 175589-02-3.mol

Chemical Properties

• Boiling Point: 230.6°Cat760mmHg
• Flash Point: 93.3°C
• Appearance: /
• Density: 1.703g/cm³
• Vapor Pressure: 0.0988mmHg at 25°C
• Refractive Index: 1.528
• CAS DataBase Reference: 5-BROMO-2-(AMINOMETHYL)-1,3-DIFLUOROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-(AMINOMETHYL)-1,3-DIFLUOROBENZENE(175589-02-3)
• EPA Substance Registry System: 5-BROMO-2-(AMINOMETHYL)-1,3-DIFLUOROBENZENE(175589-02-3)

Safety Data

• Hazardous Substances Data: 175589-02-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-BROMO-2-(AMINOMETHYL)-1,3-DIFLUOROBENZENE is used as a building block in organic synthesis for the creation of various drugs and medicinal compounds. Its versatile properties and reactivity make it a valuable component in the development of new chemical entities with potential therapeutic applications.
Used in Pharmaceutical Research:
In pharmaceutical research, 5-BROMO-2-(AMINOMETHYL)-1,3-DIFLUOROBENZENE serves as a key intermediate in the synthesis of innovative drugs. Its unique structure allows for the exploration of new chemical pathways and the enhancement of drug efficacy and selectivity.
Used in Agrochemical Production:
5-BROMO-2-(AMINOMETHYL)-1,3-DIFLUOROBENZENE is utilized in the production of agrochemicals, where its reactivity and functional groups contribute to the development of effective and targeted pest control agents.
Used in Dye Manufacturing:
In the dye industry, 5-BROMO-2-(AMINOMETHYL)-1,3-DIFLUOROBENZENE is employed for the synthesis of specialty dyes. Its chemical properties enable the creation of dyes with specific color characteristics and stability.
Used in Specialty Chemicals:
5-BROMO-2-(AMINOMETHYL)-1,3-DIFLUOROBENZENE is also used in the production of other specialty chemicals, where its versatile properties and reactivity are harnessed to create compounds with unique applications across various industries.

InChI:InChI=1/C7H4BrClF2/c8-4-1-6(10)5(3-9)7(11)2-4/h1-2H,3H2

Upstream product

• 162744-59-4 (4-bromo-2,6-difluoro-phenyl)methanol 
• 124-63-0 methanesulfonyl chloride 
• 537013-51-7 4-bromo-2,6-difluorobenzaldehyde 

Downstream Products

• 1402673-66-8 tert-butyl N-[(4-bromo-2,6-difluorophenyl)methyl]carbamate 
• 633336-82-0 tert-butyl N-[(4-cyano-2,6-difluorophenyl)methyl]carbamate 
• 433939-94-7 tert-butyl N-([2,6-difluoro-4-[N-hydroxycarbamimidoyl]phenyl]methyl)carbamate 
• 433939-95-8 tert-butyl N-[(4-carbamimidoyl-2,6-difluorophenyl)methyl]carbamate 

Relevant articles and documents

NOVEL 5-AMINO-2-THIOIMIDAZOLE COMPOUNDS AND THEIR USE

The present invention is directed to novel compounds of formula (I) pharmaceutically acceptable salts or solvates thereof, and their use.

Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance

The role of the G-protein-coupled bile acid receptor TGR5 in various organs, tissues, and cell types, specifically in intestinal endocrine L-cells and brown adipose tissue, has made it a promising therapeutical target in several diseases, especially type-2 diabetes and metabolic syndrome. However, recent studies have shown deleterious on-target effects of systemic TGR5 agonists. To avoid these systemic effects while stimulating glucagon-like peptide-1 (GLP-1) secreting enteroendocrine L-cells, we have designed TGR5 agonists with low intestinal permeability. In this article, we describe their synthesis, characterization, and biological evaluation. Among them, compound 24 is a potent GLP-1 secretagogue, has low effect on gallbladder volume, and improves glucose homeostasis in a preclinical murine model of diet-induced obesity and insulin resistance, making the proof of concept of the potential of topical intestinal TGR5 agonists as therapeutic agents in type-2 diabetes.

BRIDGED BICYCLIC KALLIKREIN INHIBITORS

Provided herein are kallikrein modulating compounds, pharmaceutical compositions comprising the same, and uses thereof.